Refills and supply gaps: a checklist before you run low
Check refills, coverage and your prescriber’s office before your supply is low, not after. Your prescriber and pharmacist know the rules for your product and plan. If a gap happens, ask them what the label and your care plan say, and do not switch products or sources on your own. In a 2025 KFF survey, cost was one of the most common reasons people gave for no longer using a GLP-1 drug.
Sources checked against Europe PMC abstracts and FDA/DailyMed label text: Nov 17, 2026; full text not read for abstract-only claims (recheck on publication date)
Quick answer
Check refills, coverage and your prescriber’s office before your supply is low, not after. Your prescriber and pharmacist know the rules for your product and plan. If a gap happens, ask them what the label and your care plan say, and do not switch products or sources on your own. In a 2025 KFF survey, cost was one of the most common reasons people gave for no longer using a GLP-1 drug.
What the survey shows

Cost and stopping, KFF 2025
In a KFF poll fielded October 27 to November 2, 2025 (1,350 U.S. adults), 56% of adults who have taken GLP-1 drugs said it was difficult to afford them, and 27% of users with health insurance said they paid the full cost themselves. Among adults who have ever taken these drugs, 14% said they were no longer using them because of cost, 13% because of side effects and 5% because their condition improved. The user figures come from a subgroup with a larger margin of error, and the answers are self-reported. Source: KFF Health Tracking Poll, November 2025.
A checklist before you run low
- Find out how much medicine you have left by checking your product and your pharmacy record, and note the date.
- Ask your pharmacy how many refills remain and what it needs to process the next one.
- Ask your prescriber’s office whether a new prescription, a visit or lab work is needed first, and how much notice they need.
- Check your plan for prior authorization, renewal dates and limits. See the article on prior authorization.
- Ask whether your plan or pharmacy requires a specific pharmacy, mail order or a specific product form.
- Write down who to call, the pharmacy phone number and the prescription number.
- Ask what to do if the pharmacy cannot fill it on time, and who decides about alternatives.
If supply is short
FDA declared the semaglutide injection shortage resolved on February 21, 2025, and its shortage file records the tirzepatide injection shortage as resolved in December 2024. Local supply gaps can still occur. Source: FDA order, semaglutide; FDA memo, tirzepatide.
If a pharmacy cannot fill your prescription, ask your prescriber and pharmacist what to do. This page does not say how to handle a missed or delayed dose or how to switch products. Use the product’s Medication Guide and talk with your care team. See the article on missed or delayed doses. For compounded or unapproved products, see FDA’s page on unapproved GLP-1 drugs: FDA.
What this does not establish
The survey describes self-reported cost and stopping among U.S. adults. It does not show refill outcomes, how often gaps occur, or what any pharmacy or plan will do. Shortage status and coverage rules change.
FAQs
What should I check about refills and supply gaps? Remaining refills, what your prescriber and plan need, and how much notice each requires.
Which official instructions or documents should I use? Your product’s Medication Guide and label, your plan’s drug list and prior authorization criteria, and FDA’s shortage pages.
Who should I contact if the product or supply seems uncertain? Your pharmacist and prescriber’s office first.